CeliacCeliac Disease Pipeline Insights: Analysis of Emerging Therapies, Key Pharma Players and Novel Approaches

18 Mar 2021
www.globenewswire.com
AcquisitionCollaborate
Los Angeles, USA, March 17, 2021 (GLOBE NEWSWIRE) -- Celiac Disease Pipeline Insights: Analysis of Emerging Therapies, Key Pharma Players and Novel Approaches CeliacCeliac disease pipeline report provides an analysis of 18+ key companies and 18+ key pipeline therapies. Larazotide by 9 Metres Biopharma represents the only Phase 3 therapeutic in development for celiac disease, with interim analysis expected in the first half of 2021. DelveInsight’s  “Celiac Disease Pipeline Insights, 2021” report puts forward detailed insights into the present clinical development landscape of the therapeutic agents and upcoming trends owing to the launch of the therapies. The report is designed to help its clients to have a clearer understanding of the Celiac disease pipeline landscape, key companies working to develop Celiac disease treatments, novel therapies under clinical trials and investigations segmented into stages of their clinical development, therapeutic assessment on the basis of RoA, MoA and so on. Gain rich insights into recent happenings, NDA approvals (if any), collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details and product development activities in the Celiac disease domain. Want to learn more about the leading candidates in different clinical stages of trials? Reach out @ Celiac Disease Pipeline Insights Celiac Disease: Overview Celiac disease is an autoimmune disorder that occurs in individuals who develop an immune reaction to gluten. Celiac disease symptoms in adults include weight loss, abdominal bloating, constipation or diarrhea, vomiting, and pale, fatty, foul-smelling stools. Celiac disease gets genetically inherited and is diagnosed with the help of blood tests. People suffering from Celiac disease are at two times greater risk of developing coronary artery disease and four times higher risk of getting bowel cancers. At present, the only option available to the patients for its treatment is lifelong adherence to a strict gluten-free diet as there is no available Celiac disease cure. However, the scientific community and pharmaceutical companies are energetically driving the development of pipeline therapies forward. Some of the key pointers extracted from the Celiac disease pipeline landscape report: Interested in knowing more? Request for the sample @ Celiac Disease Drug in Development The Celiac disease drugs pipeline report proffers a crystal clear view of the celiac disease treatments, drugs in development, clinical trial activity, patent information of the Celiac disease drugs, and collaborations and licensing in the space to help clients get a holistic view of the domain. The report is designed to help clients get a better understanding of the pipeline therapeutic activity, gauge the Celiac disease pipeline domain and opt for strategies that are set to yield better RoI with minimum risks. Want to learn more about the leading candidates in different clinical stages of trials? Reach out @ Celiac Disease Pipeline Insights At a Glance: Celiac Disease Emerging Drugs and Therapies Read more @ Celiac Disease Pipeline Activity Celiac Disease Therapeutic Assessment By Product Type By Stage By Route of Administration By Molecule Type By Mechanism of Action By Targets By Stage and Molecule TypeBy Stage and Route of AdministrationBy Stage and Product Type To know more, Visit Celiac Disease Pipeline Landscape Scope of the report Coverage: GlobalKey Players:  9 Metres Biopharma, Amgen, Allero Therapeutics, Takeda, Calypso Biotech, Anokion, Zedira GmbH, Millennium Pharmaceuticals, ImmunogenX, GlaxoSmithKline, ImmusanT, ActoBio Therapeutics, Amyra biotech and several others.Key Celiac disease Pipeline Therapies: Larazotide, Latiglutenase, AMG 714/ PRV-015, TAK-101, ZED1227, CALY 002, KAN 101, PvP001, GSKGSK 3915393, ALL-001 and several others. Key Questions Answered in Celiac Disease Pipeline Assessment Report Got queries? We will be happy to resolve. Drop by @ Celiac Disease Drugs, Therapies and Pipeline Review Table of Contents Related Reports Celiac Disease MarketDelveInsight’s ‘Celiac Disease (CD) Market Insights, Epidemiology and Market Forecast– 2030’ report. Behcet’s Disease MarketDelveInsight's "Behcet's Disease Market Insights, Epidemiology, and Market Forecast-2030" report. Alopecia Areata MarketDelveInsight's "Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2030" report. Chronic Plaque Psoriasis MarketDelveInsight's "Chronic Plaque Psoriasis - Market Insights, Epidemiology, and Market Forecast-2030" report. Bullous Pemphigoid MarketDelveInsight's "Bullous Pemphigoid Market Insights, Epidemiology, and Market Forecast-2030" report. Angioedema MarketDelveInsight's "Angioedema Market Insights, Epidemiology, and Market Forecast-2030" report. Autoimmune Hepatitis MarketDelveInsight's "Autoimmune Hepatitis Market Insights, Epidemiology, and Market Forecast-2030" report. Chronic Inflammatory Demyelinating Polyradiculoneuropathy MarketDelveInsight's "Chronic Inflammatory Demyelinating Polyradiculoneuropathy - Market Insights, Epidemiology, and Market Forecast-2030" report. US Healthcare Outlook ReportDelveInsight’s “US Healthcare Outlook Report, 2020,” report. Medulloblastoma MarketDelveInsight's "Medulloblastoma - Market Insights, Epidemiology, and Market Forecast-2030" report. SARS Coronavirus Infection MarketDelveInsight's "Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Market Insights, Epidemiology, and Market Forecast-2030" report. Schistosomiasis MarketDelveInsight's "Schistosomiasis Market Insights, Epidemiology, and Market Forecast-2030" report. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.